Crebbp Loss Drives Small Cell Lung Cancer and Increases Sensitivity to HDAC Inhibition

Deshui Jia, Arnaud Augert, Dong Wook Kim, Emily Eastwood, Nan Wu, Ali H. Ibrahim, Kee Beom Kim, Colin T. Dunn, Smitha P.S. Pillai, Adi F Gazdar, Hamid Bolouri, Kwon Sik Park, David MacPherson

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

CREBBP, encoding an acetyltransferase, is among the most frequently mutated genes in small cell lung cancer (SCLC), a deadly neuroendocrine tumor type. We report acceleration of SCLC upon Crebbp inactivation in an autochthonous mouse model. Extending these observations beyond the lung, broad Crebbp deletion in mouse neuroendocrine cells cooperated with Rb1/Trp53 loss to promote neuroendocrine thyroid and pituitary carcinomas. Gene expression analyses showed that Crebbp loss results in reduced expression of tight junction and cell adhesion genes, including Cdh1, across neuroendocrine tumor types, whereas suppression of Cdh1 promoted transformation in SCLC. CDH1 and other adhesion genes exhibited reduced histone acetylation with Crebbp inactivation. Treatment with the histone deacetylase (HDAC) inhibitor Pracinostat increased histone acetylation and restored CDH1 expression. In addition, a subset of Rb1/Trp53/Crebbp-deficient SCLC exhibited exceptional responses to Pracinostat in vivo Thus, CREBBP acts as a potent tumor suppressor in SCLC, and inactivation of CREBBP enhances responses to a targeted therapy.Significance: Our findings demonstrate that CREBBP loss in SCLC reduces histone acetylation and transcription of cellular adhesion genes, while driving tumorigenesis. These effects can be partially restored by HDAC inhibition, which exhibited enhanced effectiveness in Crebbp-deleted tumors. These data provide a rationale for selectively treating CREBBP-mutant SCLC with HDAC inhibitors. Cancer Discov; 8(11); 1422-37.

Original languageEnglish (US)
Pages (from-to)1422-1437
Number of pages16
JournalCancer Discovery
Volume8
Issue number11
DOIs
StatePublished - Nov 1 2018

Fingerprint

Histone Deacetylases
Small Cell Lung Carcinoma
Acetylation
Histones
Histone Deacetylase Inhibitors
Neuroendocrine Tumors
Genes
Neuroendocrine Carcinoma
Neoplasms
Neuroendocrine Cells
Acetyltransferases
Tight Junctions
Pituitary Neoplasms
Thyroid Neoplasms
Cell Adhesion
Carcinogenesis
Gene Expression
Lung

ASJC Scopus subject areas

  • Oncology

Cite this

Jia, D., Augert, A., Kim, D. W., Eastwood, E., Wu, N., Ibrahim, A. H., ... MacPherson, D. (2018). Crebbp Loss Drives Small Cell Lung Cancer and Increases Sensitivity to HDAC Inhibition. Cancer Discovery, 8(11), 1422-1437. https://doi.org/10.1158/2159-8290.CD-18-0385

Crebbp Loss Drives Small Cell Lung Cancer and Increases Sensitivity to HDAC Inhibition. / Jia, Deshui; Augert, Arnaud; Kim, Dong Wook; Eastwood, Emily; Wu, Nan; Ibrahim, Ali H.; Kim, Kee Beom; Dunn, Colin T.; Pillai, Smitha P.S.; Gazdar, Adi F; Bolouri, Hamid; Park, Kwon Sik; MacPherson, David.

In: Cancer Discovery, Vol. 8, No. 11, 01.11.2018, p. 1422-1437.

Research output: Contribution to journalArticle

Jia, D, Augert, A, Kim, DW, Eastwood, E, Wu, N, Ibrahim, AH, Kim, KB, Dunn, CT, Pillai, SPS, Gazdar, AF, Bolouri, H, Park, KS & MacPherson, D 2018, 'Crebbp Loss Drives Small Cell Lung Cancer and Increases Sensitivity to HDAC Inhibition', Cancer Discovery, vol. 8, no. 11, pp. 1422-1437. https://doi.org/10.1158/2159-8290.CD-18-0385
Jia, Deshui ; Augert, Arnaud ; Kim, Dong Wook ; Eastwood, Emily ; Wu, Nan ; Ibrahim, Ali H. ; Kim, Kee Beom ; Dunn, Colin T. ; Pillai, Smitha P.S. ; Gazdar, Adi F ; Bolouri, Hamid ; Park, Kwon Sik ; MacPherson, David. / Crebbp Loss Drives Small Cell Lung Cancer and Increases Sensitivity to HDAC Inhibition. In: Cancer Discovery. 2018 ; Vol. 8, No. 11. pp. 1422-1437.
@article{d3b86847714742209b5272cf63b79d46,
title = "Crebbp Loss Drives Small Cell Lung Cancer and Increases Sensitivity to HDAC Inhibition",
abstract = "CREBBP, encoding an acetyltransferase, is among the most frequently mutated genes in small cell lung cancer (SCLC), a deadly neuroendocrine tumor type. We report acceleration of SCLC upon Crebbp inactivation in an autochthonous mouse model. Extending these observations beyond the lung, broad Crebbp deletion in mouse neuroendocrine cells cooperated with Rb1/Trp53 loss to promote neuroendocrine thyroid and pituitary carcinomas. Gene expression analyses showed that Crebbp loss results in reduced expression of tight junction and cell adhesion genes, including Cdh1, across neuroendocrine tumor types, whereas suppression of Cdh1 promoted transformation in SCLC. CDH1 and other adhesion genes exhibited reduced histone acetylation with Crebbp inactivation. Treatment with the histone deacetylase (HDAC) inhibitor Pracinostat increased histone acetylation and restored CDH1 expression. In addition, a subset of Rb1/Trp53/Crebbp-deficient SCLC exhibited exceptional responses to Pracinostat in vivo Thus, CREBBP acts as a potent tumor suppressor in SCLC, and inactivation of CREBBP enhances responses to a targeted therapy.Significance: Our findings demonstrate that CREBBP loss in SCLC reduces histone acetylation and transcription of cellular adhesion genes, while driving tumorigenesis. These effects can be partially restored by HDAC inhibition, which exhibited enhanced effectiveness in Crebbp-deleted tumors. These data provide a rationale for selectively treating CREBBP-mutant SCLC with HDAC inhibitors. Cancer Discov; 8(11); 1422-37.",
author = "Deshui Jia and Arnaud Augert and Kim, {Dong Wook} and Emily Eastwood and Nan Wu and Ibrahim, {Ali H.} and Kim, {Kee Beom} and Dunn, {Colin T.} and Pillai, {Smitha P.S.} and Gazdar, {Adi F} and Hamid Bolouri and Park, {Kwon Sik} and David MacPherson",
year = "2018",
month = "11",
day = "1",
doi = "10.1158/2159-8290.CD-18-0385",
language = "English (US)",
volume = "8",
pages = "1422--1437",
journal = "Cancer Discovery",
issn = "2159-8274",
publisher = "American Association for Cancer Research Inc.",
number = "11",

}

TY - JOUR

T1 - Crebbp Loss Drives Small Cell Lung Cancer and Increases Sensitivity to HDAC Inhibition

AU - Jia, Deshui

AU - Augert, Arnaud

AU - Kim, Dong Wook

AU - Eastwood, Emily

AU - Wu, Nan

AU - Ibrahim, Ali H.

AU - Kim, Kee Beom

AU - Dunn, Colin T.

AU - Pillai, Smitha P.S.

AU - Gazdar, Adi F

AU - Bolouri, Hamid

AU - Park, Kwon Sik

AU - MacPherson, David

PY - 2018/11/1

Y1 - 2018/11/1

N2 - CREBBP, encoding an acetyltransferase, is among the most frequently mutated genes in small cell lung cancer (SCLC), a deadly neuroendocrine tumor type. We report acceleration of SCLC upon Crebbp inactivation in an autochthonous mouse model. Extending these observations beyond the lung, broad Crebbp deletion in mouse neuroendocrine cells cooperated with Rb1/Trp53 loss to promote neuroendocrine thyroid and pituitary carcinomas. Gene expression analyses showed that Crebbp loss results in reduced expression of tight junction and cell adhesion genes, including Cdh1, across neuroendocrine tumor types, whereas suppression of Cdh1 promoted transformation in SCLC. CDH1 and other adhesion genes exhibited reduced histone acetylation with Crebbp inactivation. Treatment with the histone deacetylase (HDAC) inhibitor Pracinostat increased histone acetylation and restored CDH1 expression. In addition, a subset of Rb1/Trp53/Crebbp-deficient SCLC exhibited exceptional responses to Pracinostat in vivo Thus, CREBBP acts as a potent tumor suppressor in SCLC, and inactivation of CREBBP enhances responses to a targeted therapy.Significance: Our findings demonstrate that CREBBP loss in SCLC reduces histone acetylation and transcription of cellular adhesion genes, while driving tumorigenesis. These effects can be partially restored by HDAC inhibition, which exhibited enhanced effectiveness in Crebbp-deleted tumors. These data provide a rationale for selectively treating CREBBP-mutant SCLC with HDAC inhibitors. Cancer Discov; 8(11); 1422-37.

AB - CREBBP, encoding an acetyltransferase, is among the most frequently mutated genes in small cell lung cancer (SCLC), a deadly neuroendocrine tumor type. We report acceleration of SCLC upon Crebbp inactivation in an autochthonous mouse model. Extending these observations beyond the lung, broad Crebbp deletion in mouse neuroendocrine cells cooperated with Rb1/Trp53 loss to promote neuroendocrine thyroid and pituitary carcinomas. Gene expression analyses showed that Crebbp loss results in reduced expression of tight junction and cell adhesion genes, including Cdh1, across neuroendocrine tumor types, whereas suppression of Cdh1 promoted transformation in SCLC. CDH1 and other adhesion genes exhibited reduced histone acetylation with Crebbp inactivation. Treatment with the histone deacetylase (HDAC) inhibitor Pracinostat increased histone acetylation and restored CDH1 expression. In addition, a subset of Rb1/Trp53/Crebbp-deficient SCLC exhibited exceptional responses to Pracinostat in vivo Thus, CREBBP acts as a potent tumor suppressor in SCLC, and inactivation of CREBBP enhances responses to a targeted therapy.Significance: Our findings demonstrate that CREBBP loss in SCLC reduces histone acetylation and transcription of cellular adhesion genes, while driving tumorigenesis. These effects can be partially restored by HDAC inhibition, which exhibited enhanced effectiveness in Crebbp-deleted tumors. These data provide a rationale for selectively treating CREBBP-mutant SCLC with HDAC inhibitors. Cancer Discov; 8(11); 1422-37.

UR - http://www.scopus.com/inward/record.url?scp=85055914961&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055914961&partnerID=8YFLogxK

U2 - 10.1158/2159-8290.CD-18-0385

DO - 10.1158/2159-8290.CD-18-0385

M3 - Article

C2 - 30181244

AN - SCOPUS:85055914961

VL - 8

SP - 1422

EP - 1437

JO - Cancer Discovery

JF - Cancer Discovery

SN - 2159-8274

IS - 11

ER -